Circulating T cell status and molecular imaging may predict clinical benefit of neoadjuvant PD-1 blockade in oral cancer.

J Immunother Cancer · 2024 · PMC11268040 · PMID 39038919

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

13 14 In this study, baseline SUV peak of 18 F-BMS-986192 showed a trend to be higher in patients with versus without a MPR (median SUV peak 5.3 vs 3.4).

also in 53,322 other papers

borderline significantno p-value reported

Of note, due to the low number of responders (n=3), observed differences were often not or borderline significant, warranting caution in overinterpretation.

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.